Literature DB >> 15020304

Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits.

Anindita Das1, Ramzi Ockaili, Fadi Salloum, Rakesh C Kukreja.   

Abstract

Sildenafil citrate (Viagra) is the most widely used pharmacological drug for treating erectile dysfunction in men. It has potent cardioprotective effects against ischemia-reperfusion injury via nitric oxide and opening of mitochondrial ATP-sensitive K(+) channels. We further investigated the role of protein kinase C (PKC)-dependent signaling pathway in sildenafil-induced cardioprotection. Rabbits were treated (orally) with sildenafil citrate (1.4 mg/kg) 30 min before index ischemia for 30 min and reperfusion for 3 h. The PKC inhibitor chelerythrine (5 mg/kg i.v.) was given 5 min before sildenafil. Infarct size (% of risk area) reduced from 33.65 +/- 2.17 in the vehicle (saline) group to 15.07 +/- 0.63 in sildenafil-treated groups, a 45% reduction compared with vehicle (mean +/- SE, P < 0.05). Chelerythrine abolished sildenafil-induced protection, as demonstrated by increase in infarct size to 31.14 +/- 2.4 (P < 0.05). Chelerythrine alone had an infarct size of 33.5 +/- 2.5, which was not significantly different compared with DMSO-treated group (36.8 +/- 1.7, P > 0.05). Western blot analysis demonstrated translocation of PKC-alpha, -, and -delta isoforms from cytosol to membrane after treatment with sildenafil. However, no change in the PKC-beta and -epsilon isoforms was observed. These data provide direct evidence of an essential role of PKC, and potentially PKC-alpha, -, and -delta, in sildenafil-induced cardioprotection in the rabbit heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020304     DOI: 10.1152/ajpheart.01040.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  30 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

Authors:  Jane L Roberts; Laurence Booth; Adam Conley; Nichola Cruickshanks; Mark Malkin; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

3.  Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.

Authors:  Fadi N Salloum; Vinh Q Chau; Nicholas N Hoke; Antonio Abbate; Amit Varma; Ramzi A Ockaili; Stefano Toldo; Rakesh C Kukreja
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

Review 4.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

5.  Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Adam Conley; David E Durrant; Anindita Das; Paul B Fisher; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Mol Pharmacol       Date:  2013-12-18       Impact factor: 4.436

6.  Enhanced vascular PI3K/Akt-NOX signaling underlies the peripheral NMDAR-mediated pressor response in conscious rats.

Authors:  Marie A McGee; Abdel A Abdel-Rahman
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

7.  Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole.

Authors:  Chengqun Huang; Wayne Liu; Cynthia N Perry; Smadar Yitzhaki; Youngil Lee; Hua Yuan; Yayoi Tetsuo Tsukada; Anne Hamacher-Brady; Robert M Mentzer; Roberta A Gottlieb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

8.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Authors:  Anindita Das; Fadi N Salloum; Lei Xi; Yuan J Rao; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

9.  Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction.

Authors:  Janet R Manning; Sarah O Perkins; Elizabeth A Sinclair; Xiaoqian Gao; Yu Zhang; Gilbert Newman; W Glen Pyle; Jo El J Schultz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-11       Impact factor: 4.733

Review 10.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.